Press Releases

Drug Safety Alliance to Sponsor and Present at DIA’s Pharmacovigilance and Risk Management Strategies 2012

The company’s Chief Safety Officer will present on Monday, January 23

(Research Triangle Park, N.C.) – January 19, 2012 – Drug Safety Alliance, Inc., a privately held, woman-owned business, is helping life-science partners gain new agility in responding to change with safety and pharmacovigilance solutions that blend industry knowledge, targeted services, technology and functional expertise. The company will sponsor and present at the DIA Pharmacovigilance and Risk Management Strategies meeting on Monday, January 23 through Wednesday, January 25, 2012. Chief Safety Officer Elizabeth Garrard, PharmD, RPh, will review the latest on the use of social media in pharmacovigilance and assess the view toward social media use among major players in the pharmaceutical industry.

Dr. Garrard’s program will focus on the incredible growth of social media and the impact of that growth on pharmaceutical organizations. It will also cover the most up-to-date statistics regarding adverse event reporting through social media outlets, and the FDA’s most recent communication on the subject.

“It’s clear that adverse event reporting through social media is on the radar of many pharmaceutical organizations today,” said Dr. Garrard. “As a company focused on drug safety, we want to help those organizations understand their responsibilities with regard to adverse events posted on Web 2.0 platforms.”

Details on Dr. Garrard’s presentation are as follows:

Presentation: AE Reporting in the Era of Web 2.0: The Challenges of Having a Two-Way Conversation
Date/Time: Monday, January 23, 2012, 4:30 p.m. – 5:15 p.m.
Location: Sheraton National Hotel, Arlington, VA

DIA’s Pharmacovigilance and Risk Management Strategies conference brings together the top pharmaceutical, biotech and regulatory representatives to discuss the current complexities and controversies in pharmacovigilance and risk management throughout all phases of development and marketed use, new and updated legislation in various ICH regions, important new harmonization initiatives, life cycle management, the impact of social media, biosimilars, and the use of other data sources and observational research. For more information about the conference go to: http://meetings.diahome.org/12002/.

About Drug Safety Alliance
Drug Safety Alliance, Inc. (DSA) is a global leader in safety and risk management services supporting pharmaceutical, biotech, medical device, consumer health and animal health organizations. Uniquely focused on pharmacovigilance, DSA provides comprehensive outsourced solutions and modified services to augment existing safety departments.

DSA strives to promote patient safety and product longevity by fostering the open exchange of ideas among organizations throughout the pharmacovigilance community. By developing innovative approaches to post-marketing and clinical case processing, adverse event reporting, risk evaluation and mitigation, information technology services, medical services and signal management, DSA is helping to advance the practice of pharmacovigilance.

DSA is a privately held, woman-owned business headquartered in Research Triangle Park, North Carolina.

# # #